According to BioMS Medical, an independent monitoring board has recommended that a phase II/III study of dirucotide (MBP8298) in patients with secondary progressive MS should continue to completion. And that milestone is worth a $10 million payment from Eli Lilly, which is partnered on the project.
The interim analysis assessed the likelihood of the study reaching its primary endpoint in patients with a particular immune response genes. The DSMB analysis also included a scheduled review of safety information.
- check out the BioMS release